ImmunityBio (IBRX) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmunityBio (IBRX) has outperformed Repligen (RGEN) over the past year, gaining 291.7% versus a gain of 8.6%. Over five years, IBRX leads with a +6.6% price change compared with -38.6% for RGEN. ImmunityBio is the larger company by market cap ($11.14 billion vs $11.04 billion), about 1.0 times the size.
Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | RGEN |
|---|---|---|
| Share price | $10.51 | $173.88 |
| Market cap | $11.14B | $11.04B |
| 1-day change | +6.05% | +6.13% |
| YTD return | +400.51% | -0.01% |
| 1-year return | +291.70% | +8.64% |
| 5-year return | +6.56% | -38.62% |
| P/E ratio (TTM) | — | 238.19 |
| Forward P/E | — | 65.68 |
| EPS (TTM) | $-0.96 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $738.26M |
| Revenue growth (YoY) | +668.31% | +16.36% |
| Net income (latest FY) | $-351.40M | $48.89M |
| Gross margin | 99.34% | 52.32% |
| Operating margin | -226.00% | 7.47% |
| Net margin | -310.18% | 6.62% |
| 52-week high | $12.43 | $198.87 |
| 52-week low | $1.95 | $100.99 |
| Distance from 52-week high | -15.45% | -12.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.31% | +12.12% |
| Average volume | 10.28M | 1.18M |
| Shares outstanding | 1.06B | 63.49M |
| Employees | 684 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed RGEN by 283.1 percentage points over the past year.
- Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +16.36%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
IBRX vs RGEN FAQ
Which is bigger, ImmunityBio or Repligen?
ImmunityBio (IBRX) is larger, with a market capitalization of $11.14B compared with $11.04B for Repligen (RGEN).
Which stock has performed better over the past year, IBRX or RGEN?
IBRX returned +291.70% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.